These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 39273426)

  • 1. Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors.
    Hillmen P; Horneff R; Yeh M; Kolev M; Deschatelets P
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial Approval.
    Horneff R; Czech B; Yeh M; Surova E
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
    Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
    Front Immunol; 2019; 10():1157. PubMed ID: 31258525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target.
    Risitano AM; Frieri C; Urciuoli E; Marano L
    Immunol Rev; 2023 Jan; 313(1):262-278. PubMed ID: 36110036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
    Versino F; Fattizzo B
    Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
    Heo YA
    Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
    Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R
    J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxysmal nocturnal haemoglobinuria.
    Hill A; DeZern AE; Kinoshita T; Brodsky RA
    Nat Rev Dis Primers; 2017 May; 3():17028. PubMed ID: 28516949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.
    Xu B; Kang B; Chen J; Li S; Zhou J
    Blood Rev; 2024 Jul; 66():101210. PubMed ID: 38811284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
    Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
    N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegcetacoplan: First Approval.
    Hoy SM
    Drugs; 2021 Aug; 81(12):1423-1430. PubMed ID: 34342834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
    Wong R; Fishman J; Wilson K; Yeh M; Al-Adhami M; Zion A; Yee CW; Huynh L; Duh MS
    Adv Ther; 2023 Apr; 40(4):1571-1589. PubMed ID: 36750531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond.
    Gavriilaki E; de Latour RP; Risitano AM
    Blood; 2022 Jun; 139(25):3571-3582. PubMed ID: 34482398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
    Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
    Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel anti-complement therapeutics for hemolytic anemia].
    Nishimura JI
    Rinsho Ketsueki; 2023; 64(6):466-473. PubMed ID: 37407469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.
    Merrill SA; Brodsky RA
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):371-376. PubMed ID: 30504334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
    Wong RSM
    Ther Adv Hematol; 2022; 13():20406207221114673. PubMed ID: 35923770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
    Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
    Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.